SentiSearch, Inc. - FORM 10-Q - November 14, 2011

Attached files

file	filename
EXCEL - IDEA: XBRL DOCUMENT - SentiSearch, Inc.	Financial_Report.xls
EX-31 - EXHIBIT 31 - SentiSearch, Inc.	v239844_ex31.htm
EX-32 - EXHIBIT 32 - SentiSearch, Inc.	v239844_ex32.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from ___________ to __________

Commission file number: 000-52320

SENTISEARCH, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-5655648
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

27 East 62nd Street, Suite 9D New York, NY		10065
(Address of principal executive office)		(Zip Code)

(212) 510-7905

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files.) Yes x No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨	Accelerated Filer ¨

Non-Accelerated Filer ¨ (Do not check if a smaller reporting company )	Smaller Reporting Company x

Indicated by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of November 13, 2011, the Company had outstanding 16,821,787 shares of Common Stock.

TABLE OF CONTENTS

SENTISEARCH, INC.

FORM 10-Q

	Page
PART I FINANCIAL INFORMATION

ITEM 1 Financial Statements		3

ITEM 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

ITEM 3 Quantitative and Qualitative Disclosures About Market Risk		17

ITEM 4 Controls and Procedures		17

PART II OTHER INFORMATION

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds		17

ITEM 5 Other Information		17

ITEM 6 Exhibits		18

SIGNATURES		19

PART I- FINANCIAL INFORMATION

Item 1. Financial Statements.

SENTISEARCH, INC.

Balance Sheets

ASSETS

	September 30,			December 31,
	2011			2010
	(unaudited)
Current Assets
Cash and cash equivalents	$	67,602		$	171,854
Account receivable		280,000			15,000
Security deposit		8,160			4,170
Prepaid expense		3,740			1,236
Total Current Assets		359,502			192,260

Other Assets
Account receivable		—			265,000
Total Other Assets		—			265,000

Total Assets	$	359,502		$	457,260

LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current Liabilities
Accounts payable and accrued expenses	$	453,197		$	144,706
Deferred revenue		373,750			390,000
Demand Notes payable - related parties		—			70,000
Total Current Liabilities		826,947			604,706

Other Liabilities
Deferred revenue		—			276,250
Notes payable - related parties, net		166,264			80,000
Total other Liabilities		166,264			356,250
Total Liabilities		993,211			960,956

Commitments and Contingencies		—			—

Stockholders' Deficiency
Common stock — $0.0001 par value, 20,000,000 shares authorized; 16,821,787 and 16,821,787 shares issued and outstanding, respectively		1,682			1,682
Additional paid-in capital		2,649,632			2,376,987
Accumulated deficit		(3,285,023	)		(2,882,365	)

Total Stockholders' Deficiency		(633,709	)		(503,696	)

Total Liabilities and Stockholders' Deficiency	$	359,502		$	457,260

See notes to financial statements.

SENTISEARCH, INC.

Statements of Operations (unaudited)

	For the Three months Ended						For the Nine months Ended
	September 30,						September 30,
	2011			2010			2011			2010

Revenues	$	97,500		$	16,250		$	292,500		$	16,250
Operating expenses:
General and administrative		215,021			434,941			646,384			666,130
Amortization of license and patent costs		—			—			—			42,915

		215,021			434,941			646,384			709,045
Loss before other (income) expense		(117,521	)		(418,691	)		(353,884	)		(692,795	)

Other (income) expense:
Interest income		(11	)		—			(36	)		(2	)
Interest and financing expense		26,845			807			48,810			3,657
		26,834			807			48,774			3,655

Loss before provision for income taxes		(144,355	)		(419,498	)		(402,658	)		(696,450	)

Provision for income taxes		—			—			—			—

Net loss	$	(144,355	)	$	(419,498	)	$	(402,658	)	$	(696,450	)

Basic Earnings Per Share	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.05	)
Diluted Earnings Per Share	$	(0.01	)	$	(0.02	)	$	(0.02	)	$	(0.05	)

Weighted average shares outstanding - basic		16,821,787			16,821,787			16,821,787			15,374,269
Weighted average shares outstanding - diluted		16,821,787			16,821,787			16,821,787			15,374,269

See notes to financial statements.

SENTISEARCH, INC.

Statements of Changes in Stockholders' Deficiency

					Additional
	Common Stock				Paid-in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance - January 1, 2010		12,747,844	$	1,275	$	1,963,415	$	(2,257,135	)	$	(292,445	)
Issuance of common stock for convertible promissory notes		4,073,943		407		203,290		—			203,697
Stock-based compensation expense		—		—		210,282		—			210,282
Net loss		—		—		—		(625,230	)		(625,230	)
Balance - December 31, 2010		16,821,787		1,682		2,376,987		(2,882,365	)		(503,696	)
Stock-based compensation expense (unaudited)		—		—		21,299		—			21,299
Issuance of warrants in connection with debt (unaudited)		—		—		251,346		—			251,346
Net loss (unaudited)		—		—		—		(402,658	)		(402,658	)
Balance - September 30, 2011 (unaudited)		16,821,787	$	1,682	$	2,649,632	$	(3,285,023	)	$	(633,709	)

See notes to financial statements.

SENTISEARCH, INC.

Statements of Cash Flows

	For the Nine months ended
	September 30,
	2011			2010

Cash flows from operating activities
Net loss	$	(402,658	)	$	(696,450	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		21,299			207,201
Amortization		—			42,915
Deferred revenue		(292,500	)		(16,250	)
Amortization of discount on notes payable		37,610			—

Changes in operating assets & liabilities
Increase in accounts receivable		—			(780,000	)
Increase in prepaid expense		(2,504	)		(975	)
Increase in accounts payable and accrued expenses		308,491			255,243
Increase in deferred revenue		—			780,000

Net cash used in operating activities		(330,262	)		(208,316	)

Cash flows from investing activities
Investment in security deposits		(3,990	)		—
Investment in patents		—			(6,993	)

Net cash used in investing activities		(3,990	)		(6,993	)

Cash flows from financing activities
Proceeds of notes payable - related parties		230,000			150,000
Proceeds of note payable		—			—

Net cash provided by financing activities		230,000			150,000

Decrease in cash and cash equivalents		(104,252	)		(65,309	)
Cash and cash equivalents — beginning of period		171,854			73,612

Cash and cash equivalents — end of period	$	67,602		$	8,303

Non-cash from financing activities:
Warrants issued in connection with the issuance of notes payable - related parties	$	251,346		$	—

Conversion of note payable, and related accrued interest to common stock	$	—		$	203,697

Notes to Financial Statements

1. Organization and Nature of Operations

SentiSearch, Inc. (“we,” “our”, “SentiSearch” and “the Company”) was a wholly-owned subsidiary of Sentigen Holding Corp. (“Sentigen”) until the December 1, 2006 “spin-off”, discussed below. We were incorporated in the State of Delaware on October 3, 2006 to hold the olfaction intellectual property assets of Sentigen and its subsidiaries.

On October 10, 2006, in connection with its merger with Invitrogen Corporation, Sentigen separated its olfaction intellectual property assets from the businesses being acquired by Invitrogen Corporation. The distribution of SentiSearch shares to the shareholders of Sentigen, commonly referred to as a “spin-off,” took place immediately prior to the consummation of the merger. In connection with the distribution, on October 10, 2006, we entered into a distribution agreement with Sentigen, pursuant to which Sentigen contributed $250,000 to our capital. Also on October 10, 2006, we entered into a contribution agreement with Sentigen, pursuant to which Sentigen transferred to us all of its olfaction intellectual property. The olfaction intellectual property assets primarily consist of an exclusive license agreement with The Trustees of Columbia University in the City of New York (“Columbia”), dated April 10, 2000 (the “Columbia License”), and certain patent applications titled “Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof.”

We have been issued a total of four patents in the United States. Such patents were issued in July 2007, June 2009, October 2009 and August 2010. During November 2007, we were issued one patent in Australia. During May 2009, we were issued one patent in Mexico. During October 2009, we were issued one patent in Japan and during May 2010 we were issued one patent in Israel. These patents expire between 2022 and 2023. All of the issued patents and patent applications cover nucleic acid molecules which encode insect odorant receptor proteins, including numerous variations on insect odorant receptor coding sequence and the uses of the nucleic acid molecules. The issued patents and patent applications cover any nucleic acid molecule as long as the protein it encodes contains a short segment of amino acids, linked together.

While we believe our technology capabilities in the olfaction area are substantial, up to this point, we have incurred substantial operating losses. We have generated only $406,250 of revenues from operations to date. We intend to continually review the commercial validity of our olfaction technology in order to make the appropriate decisions as to the best way to allocate our limited resources.

2. Basis of Presentation

The accompanying interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, the interim financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position as of September 30, 2011, and the results of operations, changes in stockholders’ equity and cash flows for the nine months ended September 30, 2011. The results for the nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for any subsequent quarter or the entire fiscal year ending December 31, 2011.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the Securities and Exchange Commission’s (“SEC”) rules and regulations.

These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2010 as included in the Company’s Report on Form 10-K for the year ended December 31, 2010. There have been no changes in significant accounting policies since December 31, 2010.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated significant revenue and has incurred accumulated net losses of $3,285,023 and as of September 30, 2011, has a working capital deficiency of $482,445 and a stockholders' deficiency of $633,709. The Company may need substantial amounts of additional financing to commercialize the research programs undertaken. Financing may not be available on favorable terms, or at all. The Company’s ability to obtain financing and realize revenue depends upon the status of future business prospects, as well as conditions prevailing in the capital markets. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon (i) the results of the Development Agreement, (ii) management’s plan to locate additional opportunities with non-profit agencies and/or potential commercial partners, and (iii) raising additional capital, including from the sale of stock and, ultimately, income from operations. The accompanying financial statements do not include any adjustments that might be required should the Company be unable to recover the value of its assets or satisfy its liabilities.

3. Summary of Significant Accounting Policies

a.	Cash and Cash Equivalents – Cash and cash equivalents include liquid investments with maturities of three months or less at the time of purchase. There are no cash equivalents as of the balance sheet date.

b.	Accounts Receivable - Accounts receivable are recorded at their estimated realizable value after reduction for an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts is determined primarily through specific identification and evaluation of significant past due amounts, supplemented by an estimate applied to the remaining balance, which is based on historical experience. Accounts are deemed past due when payment has not been received within the stated time period. The Company reviews individual past due amounts periodically and writes-off amounts for which all collection efforts are deemed to have been exhausted. At September 30, 2011, no allowance for uncollectible accounts is deemed necessary.

c.	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains its cash accounts at high quality financial institutions with balances, at times, in excess of federally insured limits. As of September 30, 2011, the Company had no cash balances in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance limit. Management believes that the financial institutions that hold the Company’s deposits are financially sound and therefore pose minimal credit risk. Recent Federal legislation has made permanent the FDIC deposit insurance limit of $250,000 per depositor.

d.	Estimates – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

e.	Income Taxes – The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and the tax basis of the assets and liabilities and are measured using enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized.

	The Company recognizes the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount recognized in the financial statements is the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. As of September 30, 2011, the Company is unaware of any uncertain tax positions.

f.	Loss Per Share – The accompanying financial statements include loss per share calculated as required by accounting standards on a “pro-forma” basis as if we were a separate entity from the period April 10, 2000 (commencement of business) until October 3, 2006 (our date of incorporation). Basic loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted loss per share include the effects of securities convertible into common stock, consisting of stock options, to the extent such conversion would be dilutive. Accounting standards prohibits adjusting the denominator of diluted earnings per share for additional potential common shares when a net loss from continuing operations is reported. The assumed exercise of common stock equivalents was not utilized for the nine months ended September 30, 2011 since the effect would be anti-dilutive. As of September 30, 2011, 1,125,000 options were outstanding of which 1,125,000 were exercisable.

g.	Fair Value of Financial Instruments – The Company has adopted the accounting standard for fair value measurements, as it applies to its financial statements. This standard defines fair value, outlines a framework for measuring fair value, and details the required disclosures about fair value measurements.

	Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The standard establishes a hierarchy in determining the fair value of an asset or liability. The fair value hierarchy has three levels of inputs, both observable and unobservable. The standard requires the utilization of the lowest possible level of input to determine fair value. Level 1 inputs include quoted market prices in an active market for identical assets or liabilities. Level 2 inputs are market data, other than Level 1, that are observable either directly or indirectly. Level 2 inputs include quoted market prices for similar assets or liabilities, quoted market prices in an inactive market, and other observable information that can be corroborated by market data. Level 3 inputs are unobservable and corroborated by little or no market data.

h.	Stock-Based Compensation– Stock-based compensation expense represents share-based payment awards based upon the grant date fair value estimated in accordance with accounting standards. The Company recognizes compensation expense for stock option awards on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized based upon awards ultimately expected to vest, reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

	The expected term of stock options represents the average period the stock options are expected to remain outstanding. The expected stock price volatility for the Company’s stock options was determined by examining the historical volatilities for industry peers for periods that meet or exceed the expected term of the options, using an average of the historical volatilities of the Company’s industry peers, as the Company did not have sufficient trading history for the Company’s common stock. During 2010, the Company began using the historical stock price volatility of the Company’s Common Stock to determine the expected stock price volatility as the Company believes there is sufficient historical data. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts.

	The Company accounts for its issuances of stock-based compensation to non-employees for services rendered using the measurement date guidelines enumerated in the accounting standards. Accordingly, the value of any awards that were vested and non forfeitable at their date of issuance were measured based on the fair value of the equity instruments at the date of issuance. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company’s stock and other assumptions that management believes are reasonable. The Company believes that the fair value of the stock options issued to non-employees is more reliably measurable than the fair value of the services rendered. The fair value of the stock options granted was calculated using the Black-Scholes option pricing model.

i.	Revenue Recognition - The SEC's guidance for revenue recognition requires that certain criteria must be met before revenue can be recognized; persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.

	Revenues from license agreements are recognized over the life of the agreement as they are earned. Any amounts received prior to satisfying our revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets. Deferred licensing revenue of $373,750 and $666,250 was recorded at September 30, 2011 and December 31, 2010, respectively.

j.	Recently Adopted and Issued Accounting Pronouncements

	Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a significant effect on the accompanying financial statements.

4. Development Agreement

On August 31, 2010, the Company entered into the Development Agreement with Bayer CropScience AG ("Bayer"), effective September 15, 2010, pursuant to which the Company and Bayer are cooperating in the identification and development of molecules affecting olfaction (the sense of smell) in insects. This approach is designed to exploit advances in neuroscience to safely and effectively prevent crop damage and the spread of human disease by altering insect behavior. This approach may allow for a new level of specificity and efficiency of insect control.

Under the Development Agreement, the Company provides to Bayer proprietary technology for screening particular compounds in Bayer's chemical library that may affect the function of insect odorant receptors. Bayer's efforts have been undertaken as part of a collaborative research project (the "Research Project") with investigators at Columbia and Rockefeller Universities in New York. Support for the Research Project is being provided by a grant award to Columbia from the Foundation for the National Institutes of Health (FNIH) through the Grand Challenges in Global Health initiative (the "Initiative") of the Bill & Melinda Gates Foundation. One of the goals of the Initiative is to improve the control of insects that affect human health, with the ultimate goal of eradication of malaria, Dengue fever and other insect borne diseases in the developing world.

Bayer will determine whether to develop further, for crop control applications, compounds identified in the course of the Research Project.

In connection with the Development Agreement, the Company has granted to Bayer certain exclusive rights to use the Company’s proprietary technology in the field of use of the Development Agreement (any use against invertebrate animals other than the prevention, diagnosis or treatment of human health conditions). Bayer will provide the Company with the opportunity to acquire a license in the field of use to further develop compounds identified by Bayer in the course of the Research Project, which Bayer determines not to further develop itself. Bayer has also granted the Company an exclusive option, that expires five years from the end of the Project Term, as that term is defined below, to negotiate and execute a license from Bayer with respect to compounds identified by Bayer in the course of the Research Project, for use outside the field of use and outside the field of agriculture.

As part of the Development Agreement, Bayer has paid to the Company an upfront nonrefundable $500,000 license fee and has agreed to pay to the Company additional amounts upon achieving certain milestones and royalties on any net sales of products developed pursuant to the project. Consistent with the global access policy of the Initiative and the award agreement to Columbia University from FNIH, the Development Agreement also provides for certain guidelines with respect to distribution and pricing of products for those most in need in disease endemic countries. The Development Agreement provides for a two-year Project Term through September 15, 2012.

The total contract payments of $780,000 (including the $500,000 upfront payment) were recorded as deferred revenue and classified as a short-term and long-term liability on the balance sheet to be recognized over the two-year term. License fee revenue of $292,500 was recognized during the nine months ended September 30, 2011.

5. Share-Based Payments

As of August 30, 2010, the Company and two of its consultants agreed to cancel all options issued to such individuals representing 400,000 shares previously issued in March 2008.

On September 8, 2010, the Company adopted the 2010 Stock Incentive Plan ("2010 Plan"). A total of 2,000,000 shares of common stock were eligible for issuance under the 2010 Plan. On that date, the Company granted under the 2010 Plan 500,000 stock options to an officer with an exercise price of $0.28 per share. The options vested immediately and have a ten-year term. Assumptions related to the estimated fair value of these stock options on their date of grant, which the Company estimated using the Black-Scholes option pricing model, are as follows: risk-free interest rate of approximately 2%; expected divided yield of 0%; expected option life of five years; and expected volatility of approximately 190%. The aggregate grant date fair value of the award amounted to $135,450. In addition, the Company granted 250,000 stock options to two of its directors with an exercise price of $0.28 per share. The options vested immediately and have a ten-year term. Assumptions related to the estimated fair value of these stock options on their date of grant, which the Company estimated using the Black-Scholes option pricing model, are as follows: risk-free interest rate of approximately 3%; expected divided yield of 0%; expected option life of ten years; and expected volatility of approximately 190%. The aggregate grant date fair value of the award amounted to $69,850.

On September 8, 2010, the Company also granted 50,000 stock options to an employee with an exercise price of $0.28 per share. The options vest 50% on each of July 1, 2011 and July 1, 2012 and have a ten-year term. Assumptions related to the estimated fair value of these stock options on their date of grant, which the Company estimated using the Black-Scholes option pricing model, are as follows: risk-free interest rate of approximately 2%; expected divided yield of 0%; expected option life of approximately six years; and expected volatility of approximately 190%. The aggregate grant date fair value of the award amounted to $13,700. Since July 2011, this employee has not worked for the Company. As of September 30, 2011, 25,000 unvested stock options had expired and 25,000 vested stock options are exercisable at any time until July 1, 2012.

On April 19, 2011, the Board of Directors amended the 2010 Plan to decrease the number of shares available under the 2010 Plan from 2,000,000 to 800,000. Such decrease was in effect until an amended Certificate of Incorporation was approved by the stockholders of the Company to increase the number of authorized shares of Common Stock at the annual meeting of stockholders for 2011.

On July 26, 2011, the Company granted 50,000 stock options to a consultant of the Company with an exercise price of $0.25 per share. The options vested immediately and have a ten-year term. Assumptions related to the estimated fair value of these stock options on their date of grant, which the Company estimated using the Black-Scholes option pricing model, are as follows: risk-free interest rate of approximately 1.5%; expected divided yield of 0%; expected option life of five years; and expected volatility of approximately 199%. The aggregate grant date fair value of the award amounted to $12,185.

On August 12, 2011, the Company granted 25,000 stock options to a consultant of the Company with an exercise price of $0.25per share. The options vested immediately and have a ten-year term. Assumptions related to the estimated fair value of these stock options on their date of grant, which the Company estimated using the Black-Scholes option pricing model, are as follows: risk-free interest rate of approximately 1%; expected divided yield of 0%; expected option life of five years; and expected volatility of approximately 197%. The aggregate grant date fair value of the award amounted to $6,083.

The Company recorded $21,299 and $207,201 of compensation expense for the nine months ended September 30, 2011 and 2010, respectively. At September 30, 2011, there were no unvested stock options, therefore there was no related unamortized compensation expense.

The following table summarizes information on all common stock purchase option activity for the nine months ended September 30, 2011:

	September 30, 2011
	Number			Weighted Average Exercise Price
Outstanding, beginning of the year		1,075,000		$	0.24
Granted		75,000			0.25
Cancelled		(25,000	)		(0.28	)

Outstanding, September 30, 2011		1,125,000		$	0.24

Exercisable, September 30, 2011		1,125,000		$	0.24

The number and weighted average exercise prices of all common stock purchase options as of September 30, 2011 are as follows:

Range of Exercise Prices	Remaining Number Outstanding		Weighted Average Contractual Life (Years)		Weighted Average Exercise Price

$0.05 to $0.28		1,125,000		8.12	$	0.24

All options were issued at an option price at least equal to the market price on the date of the grant, in addition, none of the options currently outstanding have any intrinsic value.

The Company issues new shares of common stock upon exercise of stock options.

6. Notes Payable

During October 2009, the Company issued to each of four individuals $50,000 principal amount of subordinated convertible promissory notes (the “October 2009 Notes”) aggregating $200,000. The individuals included the Company’s Chief Executive Officer and Chairman of the Board, another director, one of the Company’s greater than 5% stockholders and an accredited investor. The $50,000 principal amount of October 2009 Notes issued to the Chief Executive Officer and Chairman of the Board represented $25,000 of new funds received and a rollover of a $25,000 loan made by him to the Company on September 10, 2009. The October 2009 Notes bore interest of 4% per annum and were payable on demand on the earlier of (i) the date on which the Company publicly announced a joint venture or strategic relationship, the execution of a license, or similar agreement with a third-party with respect to the Company’s technology and (ii) the date on which the Company filed with the SEC its annual report on Form 10-K, which included audited financial statements for the year ended December 31, 2009, such date referred to as the target date. The holders were entitled to convert the outstanding principal amount of the October 2009 Notes and accrued and unpaid interest thereon into shares of the Company’s common stock at any time commencing on the fifth trading day immediately following the target date at the conversion price in effect on such date. The conversion price was the greater of (i) the average of the closing sale price of the Company’s common stock for the five trading days immediately following the target date and (ii) $0.05 per share.

The Company was entitled to prepay the October 2009 Notes on 20 days’ prior written notice to the holders. The Company had agreed to include the shares of common stock issuable upon conversion of the October 2009 Notes in any applicable registration statement filed by the Company with the SEC covering its equity securities.

On April 8, 2010, pursuant to the terms of the October 2009 Notes, the conversion price of the October 2009 Notes was set at $0.05. Also, on April 8, 2010, each of the holders elected to convert all of the then outstanding principal and interest on such October 2009 Notes, totaling $203,697, which resulted in the issuance to them of an aggregate of 4,073,943 shares of the Company’s common stock. The conversion of the October 2009 Notes resulted in the October 2009 Notes being satisfied in full.

On April 12, 2010, the Company issued to each of four individuals $20,000 principal amount of promissory notes (a total of $80,000 principal amount) (the “April 2010 Notes”). The investors included the Company’s Chief Executive Officer and Chairman of the Board, a director of the Company who is also a beneficial owner of more than 10% of the Company’s outstanding common stock, another beneficial owner of more than 10% of the Company's outstanding common stock and one of the Company’s greater than 5% stockholders. These April 2010 Notes bore interest at 4% per annum. Principal and accrued interest on the April 2010 Notes were payable on April 12, 2015; provided, however that the April 2010 Notes became due and payable immediately upon the Company’s consummation of an equity financing resulting in net proceeds to the Company in excess of $2,500,000.

On August 12, 2010, the Company's Chief Executive Officer made an interest free loan to the Company in the amount of $20,000 pursuant to a demand promissory note.

On September 7, 2010, the Company borrowed a total of $50,000 ($25,000 each) from a director of the Company who is also a beneficial owner of more than 10% of the Company's outstanding common stock and one of the Company’s greater than 10% stockholders. These loans were made pursuant to a demand promissory note and are non-interest bearing.

On April 19, 2011, the Company and four individuals (the "Note Holders") entered into an exchange agreement pursuant to which the Company received $230,000 in additional funds from the Note Holders and the Note Holders agreed to cancel all the outstanding notes previously issued to them, aggregating $150,000 in exchange for new promissory notes and warrants. Each individual received a new promissory note (the "New Notes"), the principal amount of each New Note is $95,000 (an aggregate principal amount of $380,000) and a warrant (each a "Warrant" and collectively the "Warrants") to purchase 463,415 shares of the common stock of the Company.

The New Notes accrue interest at a rate of six percent per annum, which interest shall be paid quarterly until April 19, 2014, at which time the outstanding principal amount, with interest accrued thereon, shall be due and payable. The New Notes shall become due and payable upon customary events of default or if the Company consummates an equity financing resulting in net proceeds of $4,000,000 or more to the Company.

The four individual holders of the Warrants issued in connection with the New Notes in the aggregate have the right to purchase 1,853,660 shares of common stock at $0.41 per share exercisable for a period of five years. The aggregate fair value of the Warrants issued, amounted to $742,391, which was determined using the Black Scholes option pricing model at $0.40 per warrant utilizing the following assumptions: expected volatility of 201.15%, risk free interest rate of 2.09%, expected term of five years and a market price of $0.41.

The Company estimated the fair value of the Warrants using the Black Scholes option pricing model. In accordance to ASC 470-20 "Debt with Conversion and Other Options", the Company allocated a portion of the proceeds from the New Notes to the Warrants. The relative fair value of the Warrants, which amounted to $251,346, was recorded as a discount to the New Notes. This amount is being accreted to interest expense over the contracted term of the New Notes.

As of September 30, 2011, the carrying value of the New Notes was $166,264. Contractual interest expense under the New Notes amounted to $37,610, which was recorded as a component of interest expense in the accompanying statements of operations for the nine months ended September 30, 2011.

7. Commitments and Contingencies

The Company entered into a one-year sublease for office space in West Palm Beach, Florida. The sublease expired in June 2010. The Company was renting on a month-to-month basis, for approximately $1,390 per month. During July 2011, the Company relocated to New York and closed its Florida office.

During February 2011, the Company began leasing an office space in New York, on a month-to-month basis for approximately $3,800 per month. The Company vacated this space in April 2011.

On July 19, 2011, the Company entered into a one-year lease for office space in New York City. The monthly rent is $3,750.

8. Related Party Transactions

Please refer to Notes 5 and 6 regarding related party transactions.

9. Stockholder's Equity

On April 19, 2011, the Company issued Warrants to purchase 1,853,600 shares of the Company's common stock to the Note Holders at an exercise price of $0.41. The Warrants expires on April 19, 2016, and contain a provision allowing for a cashless exercise. The fair value of the Warrants issued, amounted to $742,391, which was determined using the Black Scholes option pricing model at $0.40 per Warrant. The Company recorded the relative fair value as a discount to the New Notes and is being accreted to interest expense over the contracted term of the notes, which amounted to $251,346 (see note 6).

10. Subsequent Events

On November 11, 2011, the Company entered into a subscription agreement with the Note Holders pursuant to which the Company raised an aggregate of $200,000. Each Note Holder invested $50,000 and received in exchange a promissory note in favor of such investor in the amount of $50,000 (collectively, the “November 2011 Notes”) and a warrant to purchase 333,333 shares of our common stock at an exercise price of $0.15 per share (the “Warrants”).

The November 2011 Notes accrue interest at a rate of six percent per annum, which interest shall be paid quarterly until April 19, 2014, at which time the outstanding principal amount, with interest accrued thereon, shall be due and payable. The November 2011 Notes shall become due and payable upon customary events of default or if the Company consummates an equity financing resulting in net proceeds of $4,000,000 or more to the Company. The Warrants are exercisable, in whole or in part, during the period from November 11, 2011 to November 11, 2016.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-looking Information

The following discussion should be read in conjunction with our Financial Statements and Notes thereto, included elsewhere within this report. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements using terminology such as “can”, “may”, “believe”, “designed to”, “expect”, “intend to,” “plan”, “anticipate”, “estimate”, “potential” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

·	discuss our future expectations;

·	contain projections of our future results of operations or of our financial condition; and

·	state other “forward-looking” information.

We believe it is important to communicate our expectations. However, forward-looking statements involve risks and uncertainties and our actual results and the timing of certain events could differ materially from those discussed in or implied by forward-looking statements as a result of certain factors, including those set forth in our Annual Report on Form 10-K for the year ended December 31, 2010. All forward-looking statements and risk factors included in this document or in such Annual Report are made as of the date hereof or thereof, as applicable, based on information available to us as of the date such statements were made, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law.

Introduction

SentiSearch, Inc. (“SentiSearch” or “we” or “us” or “our” or the “Company”) is a Delaware corporation that was incorporated on October 3, 2006. We were previously a wholly-owned subsidiary of Sentigen and were incorporated solely for the purposes of holding the olfaction intellectual property assets of Sentigen and its then subsidiary, Sentigen Biosciences. Prior to the merger between Sentigen and Invitrogen Corporation (“Invitrogen”) that was consummated on December 1, 2006, Sentigen separated its olfaction intellectual property assets from the businesses to be acquired by Invitrogen. This separation was accomplished through the contribution of Sentigen’ s olfaction intellectual property assets to us on October 10, 2006 and the subsequent spin-off in which Sentigen distributed 100% of its ownership interest in us to its then stockholders on December 1, 2006. As a result of this spin-off, we became a public, stand-alone company.

The olfaction intellectual property assets that we hold primarily consist of an exclusive worldwide license (the “Columbia License”) issued by The Trustees of Columbia University in the City of New York (“Columbia”), as described below under the heading “Columbia License”, and certain issued patents and patent applications titled “Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof.” The olfaction intellectual property assets are also referred to in this Form 10-Q as “our olfaction intellectual property.”

Columbia License

On April 10, 2000, Sentigen Biosciences entered into the Columbia License described below. On October 10, 2006, we entered into a contribution agreement with Sentigen pursuant to which Sentigen transferred to us all of its olfaction intellectual property, including the Columbia License. On October 17, 2006, Columbia consented to the assignment of the Columbia License from Sentigen Biosciences to us subject to certain conditions, all of which have been satisfied to the extent currently required. As of January 30, 2011 the Columbia License was amended such that the license in the patents originally contained in the Columbia License were terminated and, in consideration for such termination, the royalties payable by the Company to Columbia were reduced.

The Columbia License, as amended, provides us with worldwide rights to certain of Columbia’s rights in the areas of insect chemosensation and olfaction. The Columbia License gives us an exclusive license to develop, manufacture, have made, import, use, sell, distribute, rent or lease any product or service that involves the know-how, confidential information and physical materials conveyed by Columbia to us (collectively, the “Licensed Products/Services”). In addition to certain funding requirements by Sentigen, all of which were satisfied, in consideration of the Columbia License, Columbia was issued 75,000 shares of Sentigen common stock in 2006 and will receive royalties of 0.15% of the net sales of any Licensed Products/Services.

The licenses granted to us under the Columbia License expire ten years from the first sale of any Licensed Products/Services.

Patents and Patent Applications

In addition to the Columbia License, we have certain issued patents and patent applications relating to nucleic acids and proteins of insect or 83b odorant receptor genes and their uses. These patents and patent applications relate to the isolation of a gene that appears to be ubiquitous among insects. This gene has been identified in various species of insects, including many that have a profound effect on agricultural production and human health. The identification of this gene, and the protein that it expresses, may enable the development of high-throughput screening methods to discover compounds that attract insects to a particular site (and away from one where their presence is undesirable), or develop materials that are distasteful to the insects’ sense of “smell,” thereby making agricultural products, for example, undesirable to them.

While we believe our technology capabilities in the olfaction area are substantial, up to this point, we have incurred substantial operating losses. As of September 30, 2011, we held four patents in the United States and additional patents in certain foreign countries. We also have additional pending patent applications. We cannot provide any assurance that our additional patent applications will be successful. We intend to continually review the commercial validity of our olfaction technology in order to make the appropriate decisions as to the best way to allocate our limited resources.

Development Agreement

On August 31, 2010, we entered into the Development Agreement, referred to as the Development Agreement, with Bayer CropScience AG, referred to as Bayer. The Development Agreement became effective September 15, 2010. Pursuant to the terms of the Development Agreement, we and Bayer have been cooperating in the identification and development of molecules affecting olfaction (the sense of smell) in insects. This approach is designed to exploit advances in neuroscience to safely and effectively prevent crop damage and the spread of human disease by altering insect behavior. This approach may allow for a new level of specificity and efficiency of insect control.

Under the Development Agreement, we provide to Bayer proprietary technology for screening particular compounds in Bayer's chemical library that may affect the function of insect odorant receptors. Bayer's efforts have been undertaken as part of a collaborative research project, referred to as the Research Project, with investigators at Columbia and Rockefeller Universities in New York. Support for the Research Project is being provided by a grant award to Columbia from the Foundation for the National Institutes of Health (FNIH) through the Grand Challenges in Global Health initiative, referred to as the Initiative, of the Bill & Melinda Gates Foundation. One of the goals of the Initiative is to improve the control of insects that affect human health, with the ultimate goal of eradication of malaria, Dengue fever and other insect borne diseases in the developing world.

Bayer will determine whether to develop further, for crop control applications, compounds identified in the course of the Research Project.

In connection with the Development Agreement, we have granted to Bayer certain exclusive rights to use our proprietary technology in the field of use of the Development Agreement (any use against invertebrate animals other than the prevention, diagnosis or treatment of human health conditions). Bayer will provide us with the opportunity to acquire a license in the field of use to further develop compounds identified by Bayer in the course of the Research Project, which Bayer determines not to further develop itself. Bayer has also granted to us an exclusive option, that expires five years from the end of the Project Term, as that term is defined below, to negotiate and execute a license from Bayer with respect to compounds identified by Bayer in the course of the Research Project, for use outside the field of use and outside the field of agriculture.

As part of the Development Agreement, Bayer paid us an upfront $500,000 license fee and has agreed to pay us additional amounts upon achieving certain milestones and royalties on any net sales of products developed pursuant to the Research Project. Consistent with the global access policy of the Initiative and the award agreement to Columbia from FNIH, the Development Agreement also provides for certain guidelines with respect to distribution and pricing of products for those most in need in disease endemic countries.

Total contractual payments relating to the exclusive license granted to Bayer, including the aforementioned $500,000 upfront license fee, are recognized as licensing fee revenue pro-rata over the expected two-year Project Term of the Development Agreement during which the Research Project will be undertaken (the "Project Term"), through September 15, 2012.

Critical Accounting Policies and Use of Estimates

The Company’s significant accounting policies are described in Note 3 to the Financial Statements. We believe that all of these involve the application of significant judgment and discretion by management and are therefore “critical” accounting policies. Several accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. We base our estimates and judgments on historical experience, terms of existing contracts, observance of trends in the industry, information provided by outside sources and various other assumptions that we believe to be reasonable under the circumstances.

Results of Operations

General

Primarily due to the estimated revenues to be earned under the Development Agreement described below under the heading “Development Agreement”, entered into on August 31, 2010, management has determined that the Company has commenced its planned principal operations and was no longer considered a development stage company as of September 15, 2010. We have a limited operating history. We have generated only limited revenues from operations. All losses accumulated since the commencement of our business have been considered as part of our development stage activities.

Our financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course. During the nine months ended September 30, 2011, funding was provided by proceeds of $230,000 principal amount of notes we received from investors, including related parties. During the nine months ended September 30, 2011, we recognized revenues in the aggregate amount of $292,500 or nine months of an estimated 24-month project, in connection with the Development Agreement.

Product Research and Development

We intend to continually review the commercial validity of the olfaction technology, in order to make the appropriate decisions as to the best way to allocate our limited resources. Other than the Development Agreement, we currently do not have any research and development grant applications outstanding nor can we predict whether we will receive any additional research and development funding during the next twelve (12) months. Other than amounts in connection with the Development Agreement, we are unable at this time to predict a level of spending, if any, for product research and development activities during the next twelve (12) months, all of which will be dependent upon the implementation of our business plan. Our Chief Executive Officer and Board of Directors have and intend to continue to seek opportunities with non-profit agencies and with potential commercial partners to leverage our olfaction intellectual property for the development of control agents for biting insects, in particular, insect vectors of malaria and other diseases.

Revenues

During the nine months ended September 30, 2011, we realized revenues of $292,500, attributable to the Development Agreement, compared to $16,250 during the nine months ended September 30, 2010.

Operating Expenses

For the three months ended September 30, 2011, general and administrative costs were $215,021 compared to $434,941 for the three months ended September 30, 2010. The decrease of $219,920 during the three months ended September 30, 2011 is primarily due to an decrease in professional fees of $87,395, a decrease in travel expenses of $9,034, a decrease of $190,800 in stock-based compensation expense, an increase in compensation and related payroll tax expense of $53,169 and a net increase in other miscellaneous expenses of $14,140.

For the nine months ended September 30, 2011, general and administrative costs were $646,384 compared to $666,130 for the nine months ended September 30, 2010. The decrease of $19,746 during the nine months ended September 30, 2011 is primarily due to an increase in professional fees of $9,023, a decrease in travel expenses of $37,196, an increase in compensation and related payroll tax expense of $146,781, a decrease of $185,903 in stock-based compensation expense and a net increase in other miscellaneous expenses of $47,549.

Amortization expense includes the amortization of our license and patent costs. For the three months ended September 30, 2011 and 2010, amortization expense was $0 and $0, respectively, and for the nine months ended September 30, 2011 and 2010, amortization expense was $0 and 42,915, respectively. License and patent costs have been fully amortized as of September 30, 2011. The original value of the Columbia License of $440,625 reflects the closing share price of Sentigen’ s common stock on April 10, 2000. The capitalized value of the patent costs of $119,700 mainly consists of legal and application fees.

Interest and financing expenses reflect the cost of our outstanding debt. For the three months ended September 30, 2011 and 2010, interest and financing expenses amounted to $26,845 and $807, respectively, and for the nine months ended September 30, 2011 and 2010, interest amounted to $48,810 and $3,657, respectively.

Net Loss

As a result of the foregoing, we had a net loss of $144,355, or $0.01 per share, during the three months ended September 30, 2011, compared to a net loss of $419,498, or $0.02 per share, during the three months ended September 30, 2010, and for the nine months ended September 30, 2011 and 2010, we had a net loss of $402,658, or $0.02 per share, and $696,450, or $0.05 per share, respectively.

Liquidity and Capital Resources

Our financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities. We have incurred operating losses since inception. As of September 30, 2011, we had $67,602 in cash and cash equivalents, compared to $171,854 at December 31, 2010. At September 30, 2011, we had a working capital deficiency of $482,445, compared to a working capital deficiency of $412,446 at December 31, 2010. Net cash used in operating activities for the nine months ended September 30, 2011 was $334,252, compared to $208,316 for the nine months ended September 30, 2010, an increase of $125,936.

As previously reported, on April 12, 2010, we issued to each of four individuals $20,000 principal amount of promissory notes (referred to as the April 2010 Notes, (a total of $80,000 principal amount of April 2010 Notes). The investors included Joseph Pagano, the Company’s Chief Executive Officer, Secretary, Treasurer and Chairman of the Board of Directors, Frederick R. Adler, a director of the Company and a beneficial owner of more than 10% of the Company’s outstanding common stock and Samuel A. Rozzi, a beneficial owner of more than 10% of the Company’s outstanding common stock, and one individual, referred to collectively as the Holders). Additionally, as previously reported, on September 7, 2010, we issued to each of Messrs. Rozzi and Adler, $25,000 principal amount of promissory notes, referred to as the September 2010 Notes, (a total of $50,000 principal amount of September 2010 Notes), and on August 12, 2010, we issued to Mr. Pagano $20,000 principal amount of a promissory note, referred to as the August 2010 Note.

On April 19, 2011, we and the Holders entered into an exchange agreement pursuant to which we raised $230,000 in additional funds from the Holders as follows: in exchange for the April 2010 Notes, the August 2010 Note and the September 2010 Notes, in the aggregate principal amount of $150,000, and $230,000 in cash, we issued to each Holder $95,000 principal amount in a promissory note (an aggregate principal amount of $380,000) (referred to as the April 2011 Notes), and a warrant, referred to as the April 2011 Warrants, collectively, or the April 2011 Warrant, individually, to purchase 463,415 shares of Common Stock, $0.0001 par value, at a purchase price of $0.41 per share.

The April 2011 Notes accrue interest at a rate of six percent per annum, which interest is payable quarterly until April 19, 2014, at which time the outstanding principal amount, with interest accrued thereon, will be due and payable. The April 2011 Notes will become due and payable upon customary events of default or if we consummate an equity financing resulting in net proceeds of $4,000,000 or more to us.

Each April 2011 Warrant is exercisable, in whole or in part, during the period from April 19, 2011 to April 19, 2016.

We believe that we have enough working capital to fund operations through the year ending December 31, 2011.

Our ability to obtain financing and realize revenue depends upon the status of future business prospects, as well as conditions prevailing in the capital markets. These factors, among others, raise substantial doubt about our ability to continue as a going concern should we be unable to realize revenues from our olfaction technology or raise sufficient additional funds in the future. If we are unable to raise such funds, we may need to cease our operations. Additionally, if we raise additional funds by issuing equity securities, our then-existing stockholders will likely experience dilution, depending upon the terms and conditions of such financing.

Off-Balance-Sheet Arrangements

As of September 30, 2011, we did not have any off-balance-sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Inflation

Periods of high inflation could have a material adverse impact on us to the extent that increased borrowing costs for floating rate debt (if any) may not be offset by increases in cash flow. At September 30, 2011, we had $0 in floating rate debt outstanding. There was no significant impact on our operations as a result of inflation during the nine-month period ended September 30, 2011.

Recent Accounting Pronouncements

See Note 3 to the financial statements included in Part I, Item 1 of this report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

As of September 30, 2011, Mr. Joseph K. Pagano, who is our Chief Executive Officer, Secretary and Treasurer (and principal financial officer) evaluated the effectiveness of our "disclosure controls and procedures" as defined in Rules 13a-15(e) and Rule 15d-15(e) of the Securities Exchange Act of 1934 ("Disclosure Controls"). Based upon this evaluation, Mr. Pagano concluded that the Disclosure Controls were effective, as of the date of his evaluation, in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that any information relating to us that is required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive/financial officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During the fiscal quarter ended September 30, 2011, there were no changes in our "internal control over financial reporting" as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934 (“Internal Control”), that have materially affected or are reasonably likely to materially affect our Internal Control.

PART II- OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On August 12, 2011, the Board of Directors approved the grant to Robert Reinhart, an option to purchase up to 25,000 shares of the Company’s Common Stock with an exercise price of $0.25 per share, and all of such options were exercisable immediately. These options were issued pursuant to the Company’s 2010 Stock Incentive Plan.

On July 26, 2011, the Board of Directors approved the grant to Arnold Pollard, as option to purchase up to 50,000 shares of the Company’s Common Stock with an exercise price of $0.25 per share, and all of such options were exercisable immediately. These options were non-plan options.

These issuances were made pursuant to the exemption from registration provided in Section 4 (2) of the Securities Act of 1933, as amended and the rules promulgated thereunder.

Item 5. Other Information

On November 11, 2011, the Company and each of Joseph K. Pagano, our Chairman and CEO, Frederick R. Adler, one of our directors and a beneficial owner of more than 10% of our outstanding common stock, Samuel A. Rozzi, a beneficial owner of more than 10% of our outstanding common stock and one additional investor, entered into a subscription agreement pursuant to which the Company raised an aggregate of $200,000. Each investor indicated above invested $50,000 and received in exchange a promissory note made by the Company in favor of such investor in the amount of $50,000 (each a “Note”, collectively, the “Notes”) and a warrant to purchase 333,333 shares of our common stock at an exercise price of $0.15 per share (the “Warrants”).

The Notes will accrue interest at a rate of six percent per annum, which interest will be payable quarterly until April 19, 2014, at which time the outstanding principal amount, with interest accrued and unpaid thereon, will be due and payable. The Notes will become due and payable upon customary events of default or if the Company consummates an equity financing resulting in net proceeds of $4,000,000 or more to the Company.

The Warrants are exercisable, in whole or in part, during the period from November 11, 2011 to November 11, 2016.

The Notes and Warrants were issued in private transactions pursuant to the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Act”). Each Holder has represented to the Company that he or it is an accredited investor as defined as pursuant to the Act.

Item 6. Exhibits.

Exhibit		Description
31		Certification of Chief Executive Officer and principal financial officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934.

32		Certification of Chief Executive Officer and principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SENTISEARCH, INC.

Date: November 14, 2011	/s/ Joseph K. Pagano
	Joseph K. Pagano, Chief Executive Officer and Treasurer (principal executive and financial officer)

EXHIBIT INDEX

Exhibit		Description
31		Certification of Chief Executive Officer and principal financial officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934.

32		Certification of Chief Executive Officer and principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Attached files

SentiSearch, Inc. Reports

Also read